Online inquiry

IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3719MR)

This product GTTS-WQ3719MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ3719MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13597MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA R1450
GTTS-WQ8038MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ279MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ9699MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ5331MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ14026MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ3967MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ11458MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-9447
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW